JP2001500883A - 低脂質値のためのシブトラミン類似物の使用 - Google Patents
低脂質値のためのシブトラミン類似物の使用Info
- Publication number
- JP2001500883A JP2001500883A JP10515219A JP51521998A JP2001500883A JP 2001500883 A JP2001500883 A JP 2001500883A JP 10515219 A JP10515219 A JP 10515219A JP 51521998 A JP51521998 A JP 51521998A JP 2001500883 A JP2001500883 A JP 2001500883A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- carrier
- cyclobutyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 21
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical class C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 title description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 11
- 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 9
- 208000006575 hypertriglyceridemia Diseases 0.000 claims abstract description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 7
- UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000004682 monohydrates Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 67
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 23
- 239000003085 diluting agent Substances 0.000 claims description 15
- 230000001684 chronic effect Effects 0.000 claims description 14
- KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 claims description 12
- 235000012000 cholesterol Nutrition 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 201000001320 Atherosclerosis Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 8
- 200000000007 Arterial disease Diseases 0.000 claims description 7
- 208000019622 heart disease Diseases 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 108010023302 HDL Cholesterol Proteins 0.000 claims 3
- 108010028554 LDL Cholesterol Proteins 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 description 14
- 108010010234 HDL Lipoproteins Proteins 0.000 description 12
- 102000015779 HDL Lipoproteins Human genes 0.000 description 12
- 229960005303 sibutramine hydrochloride monohydrate Drugs 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229960004425 sibutramine Drugs 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000010197 meta-analysis Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- -1 racemates Chemical compound 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- WQSACWZKKZPCHN-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N)CC(C)C)CCC1 WQSACWZKKZPCHN-UHFFFAOYSA-N 0.000 description 1
- PLXKZKLXYHLWHR-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,3-dimethylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1(C(CC(C)C)NC)CCC1 PLXKZKLXYHLWHR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 239000008009 topical excipient Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Materials For Medical Uses (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Analogue/Digital Conversion (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 高脂血症、高コレステロール血症又は高トリグリセリド血症の予防及び/又 は治療法において、その必要のあるヒトに治療学的有効量の、そのエナンチオマ ーを含む式I: [式中、R1及びR2はそれぞれ独立してH又はメチルである]の化合物又は及び製 剤学的に認容性の塩を製剤学的に認容性の希釈剤又は担持剤と組み合わせて投与 することを特徴とする、高脂血症、高コレステロール血症又は高トリグリセリド 血症の予防及び/又は治療法。 2. 式Iの化合物がN,N−ジメチル−1−[1−(4−クロロフェニル)シクロブ チル]−3−メチルブチルアミン塩酸塩である、請求項1に記載の方法。 3. 式Iの化合物が、その一水化物の形のN,N−ジメチル−1−[1−(4−ク ロロフェニル)シクロブチル]−3−メチルブチルアミン塩酸塩である、請求項1 に記載の方法。 4. 高脂血症、高コレステロール血症又は高トリグリセリド血症の予防及び/又 は治療のための薬剤製造 での、そのエナンチオマーを含む式I: [式中、R1及びR2はそれぞれ独立してH又はメチルである]の化合物及びその製 剤学的に認容性の塩の使用。 5. 式Iの化合物がN,N−ジメチル−1−[1−(4−クロロフェニル)シクロブ チル]−3−メチルブチルアミン塩酸塩である、請求項4に記載の使用。 6. 式Iの化合物がN,N−ジメチル−1−[1−(4−クロロフェニル)シクロブ チル]−3−メチルブチルアミン塩酸塩一水化物である、請求項4に記載の使用 。 7. 治療学的に有効量の、そのエナンチオマーを含む式I: [式中、R1及びR2はそれぞれ独立してH又はメチルである]の化合物及びその製 剤学的に認容性の塩を製剤学的に認容性の希釈剤又は担持剤と共に含む、高脂血 症、高コレステロール血症又は高トリグリセ リド血症の予防及び/又は治療のための製剤学的組成物。 8. 式Iの化合物がN,N−ジメチル−1−[1−(4−クロロフェニル)シクロブ チル]−3−メチルブチルアミン塩酸塩である、請求項7に記載の製剤学的組成 物。 9. 式Iの化合物がN,N−ジメチル−1−[1−(4−クロロフェニル)シクロブ チル]−3−メチルブチルアミン塩酸塩一水化物である、請求項7に記載の製剤 学的組成物。 10.人体中の脂質値を低下させる方法において、その必要のある人に請求項1に 記載の式Iの化合物を製剤学的に認容性の希釈剤又は担持剤と組み合わせて投与 することを特徴とする、人体中の脂質値を低下させる方法。 11.人体中の脂質値を低下させるための薬剤製造での、請求項4記載の式Iの化 合物の使用。 12.その症状が進展する危険性が高い人のアテローム動脈硬化症、慢性心疾患及 び/又は慢性動脈疾患の予防のための薬剤製造での、請求項4に記載の式Iの化 合物の使用。 13.請求項1に記載の式Iの化合物を製剤学的に認容性の希釈剤又は担持剤と組 み合わせてそれを必要とする人に投与することからなる、その症状が進展する危 険性が高い人のアテローム動脈硬化症、慢性心 疾患及び/又は慢性動脈疾患の予防法。 14.請求項1に記載の式Iの化合物を製剤学的に認容性の希釈剤又は担持剤と組 み合わせてそれを必要とする人に投与することからなる、人体中の高密度リポ蛋 白コレステロールの低密度リポ蛋白コレステロールに対する比を増加させる方法 。 15.人体中の高密度リポ蛋白コレステロールの低密度リポ蛋白コレステロールに 対する比を増加させるための薬剤製造での、請求項4に記載の式Iの化合物の使 用。 16.治療学的に有効な量の請求項7に記載の式Iの化合物を製剤学的に認容性の 希釈剤又は担持剤と共に含む、人体中の脂質値を低減するための製剤組成物。 17.治療学的に有効な量の請求項7に記載の式Iの化合物を製剤学的に認容性の 希釈剤又は担持剤と共に含有する、その症状が進展する危険性が高い人のアテロ ーム動脈硬化症、慢性心疾患及び/又は慢性動脈疾患を予防するための製剤組成 物。 18.治療学的に有効な量の請求項7に記載の式Iの化合物を製剤学的に認容性の 希釈剤又は担持剤と共に含有する、人体の高密度リポ蛋白コレステロールの低密 度リポ蛋白コレステロールに対する比を増加させるための製剤組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9619961.7 | 1996-09-25 | ||
GBGB9619961.7A GB9619961D0 (en) | 1996-09-25 | 1996-09-25 | Medical treatment |
PCT/EP1997/005040 WO1998013034A1 (en) | 1996-09-25 | 1997-09-15 | Use of sibutramine analogues to lower lipid levels |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001500883A true JP2001500883A (ja) | 2001-01-23 |
JP2001500883A5 JP2001500883A5 (ja) | 2005-04-07 |
JP4143126B2 JP4143126B2 (ja) | 2008-09-03 |
Family
ID=10800447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51521998A Expired - Fee Related JP4143126B2 (ja) | 1996-09-25 | 1997-09-15 | 低脂質値のためのシブトラミン類似物の使用 |
Country Status (26)
Country | Link |
---|---|
US (1) | US6187820B1 (ja) |
EP (1) | EP0973511B1 (ja) |
JP (1) | JP4143126B2 (ja) |
KR (1) | KR100573333B1 (ja) |
CN (1) | CN1173696C (ja) |
AT (1) | ATE239459T1 (ja) |
AU (1) | AU724645B2 (ja) |
BG (1) | BG64472B1 (ja) |
BR (1) | BR9711411A (ja) |
CA (1) | CA2266378C (ja) |
CZ (1) | CZ291879B6 (ja) |
DE (1) | DE69721833T2 (ja) |
DK (1) | DK0973511T3 (ja) |
ES (1) | ES2199354T3 (ja) |
GB (1) | GB9619961D0 (ja) |
HU (1) | HU224711B1 (ja) |
IL (1) | IL128820A (ja) |
NO (1) | NO991424L (ja) |
NZ (1) | NZ334550A (ja) |
PL (1) | PL190017B1 (ja) |
PT (1) | PT973511E (ja) |
RU (1) | RU2197959C2 (ja) |
SK (1) | SK284282B6 (ja) |
TR (1) | TR199900648T2 (ja) |
UA (1) | UA63916C2 (ja) |
WO (1) | WO1998013034A1 (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6974838B2 (en) | 1998-08-24 | 2005-12-13 | Sepracor Inc. | Methods of treating or preventing pain using sibutramine metabolites |
US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
US6339106B1 (en) | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
AU2007200334B8 (en) * | 1998-08-24 | 2010-10-21 | Sepracor, Inc. | Methods of using and compositions comprising dopamine reuptake inhibitors |
US6476078B2 (en) | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
US6046242A (en) * | 1998-11-27 | 2000-04-04 | Basf Aktiengesellschaft | Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence |
US6696495B2 (en) | 1998-12-02 | 2004-02-24 | Snowden Pharmaceuticals, Llc | Treatment of disorders secondary to organic impairments |
US6323242B1 (en) | 1998-12-02 | 2001-11-27 | Peter Sterling Mueller | Treatment of disorders secondary to organic impairments |
AU3894500A (en) * | 1999-03-19 | 2000-10-09 | Knoll Pharmaceutical Company | Prevention of cardiovascular disease |
US6552087B1 (en) | 1999-03-19 | 2003-04-22 | Abbott Gmbh & Co. Kg | Therapeutic agent comprising (+)-sibutramine |
US6399826B1 (en) | 1999-08-11 | 2002-06-04 | Sepracor Inc. | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
FR2814678B1 (fr) * | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
WO2002083631A1 (en) | 2001-04-13 | 2002-10-24 | Sepracor Inc. | Methods of preparing didesmethylsibutramine and other sibutramine derivatives |
RU2290924C2 (ru) * | 2002-10-05 | 2007-01-10 | Ханми Фарм. Ко., Лтд. | Фармацевтическая композиция, включающая кристаллический полугидрат метансульфоната сибутрамина |
EP1622600A1 (en) * | 2003-04-28 | 2006-02-08 | Cipla Ltd. | Pharmaceutical formulation comprising anti-obesity agent and acidulant |
US20050131074A1 (en) * | 2003-08-04 | 2005-06-16 | Beckman Kristen M. | Methods for treating metabolic syndrome |
US20050032908A1 (en) * | 2003-08-04 | 2005-02-10 | Beckman Kristen M. | Methods for treating metabolic syndrome |
KR100618176B1 (ko) | 2004-12-02 | 2006-09-01 | 휴먼팜 주식회사 | 시부트라민 주석산염, 이의 제조 방법 및 이를 포함하는약학적 조성물 |
KR20060080817A (ko) | 2005-01-06 | 2006-07-11 | 씨제이 주식회사 | 시부트라민의 디카복실산염 |
EP1846359A4 (en) * | 2005-01-06 | 2010-03-31 | Cj Cheiljedang Corp | INORGANIC ACID SALTS OF SIBUTRAMINE |
KR20060080818A (ko) | 2005-01-06 | 2006-07-11 | 씨제이 주식회사 | 시부트라민의 술폰산염 |
KR20060093564A (ko) * | 2005-02-22 | 2006-08-25 | 종근당바이오 주식회사 | 무수 시부트라민 말산염 및 이의 제조 방법 |
KR100627687B1 (ko) * | 2005-04-20 | 2006-09-25 | 주식회사 씨티씨바이오 | 시부트라민 유리염기 함유 조성물 및 이의 제조방법 |
KR100814384B1 (ko) * | 2006-02-10 | 2008-03-18 | 대화제약 주식회사 | 시부트라민 염을 함유하는 약학 조성물 및 이의 제조방법 |
US8604244B2 (en) | 2010-07-02 | 2013-12-10 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives |
US7989500B2 (en) | 2006-09-15 | 2011-08-02 | Reviva Pharmaceuticals, Inc. | Synthesis, methods of using, and compositions of cycloalkylmethylamines |
EP2083867A1 (en) * | 2006-11-22 | 2009-08-05 | SK Chemicals, Co., Ltd. | Inclusion complex of sibutramine and beta-cyclodextrin |
WO2010082216A2 (en) * | 2008-12-08 | 2010-07-22 | Matrix Laboratories Ltd | Novel salts of sibutramine and their crystal forms |
IN2014MN01407A (ja) | 2011-12-30 | 2015-07-03 | Reviva Pharmaceuticals Inc |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE52768B1 (en) * | 1981-04-06 | 1988-02-17 | Boots Co Ltd | 1-arylcyclobutylalkylamine compounds useful as therapeutic agents |
GB8531071D0 (en) * | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
GB8704777D0 (en) * | 1987-02-28 | 1987-04-01 | Boots Co Plc | Medical treatment |
JP2675573B2 (ja) * | 1988-03-31 | 1997-11-12 | 科研製薬株式会社 | 脳機能改善剤 |
IE61928B1 (en) | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
US5459164A (en) * | 1994-02-03 | 1995-10-17 | Boots Pharmaceuticals, Inc. | Medical treatment |
-
1996
- 1996-09-25 GB GBGB9619961.7A patent/GB9619961D0/en active Pending
-
1997
- 1997-09-15 CA CA002266378A patent/CA2266378C/en not_active Expired - Fee Related
- 1997-09-15 JP JP51521998A patent/JP4143126B2/ja not_active Expired - Fee Related
- 1997-09-15 US US09/269,340 patent/US6187820B1/en not_active Expired - Lifetime
- 1997-09-15 DE DE69721833T patent/DE69721833T2/de not_active Expired - Lifetime
- 1997-09-15 ES ES97910289T patent/ES2199354T3/es not_active Expired - Lifetime
- 1997-09-15 AU AU47741/97A patent/AU724645B2/en not_active Ceased
- 1997-09-15 TR TR1999/00648T patent/TR199900648T2/xx unknown
- 1997-09-15 CN CNB971982341A patent/CN1173696C/zh not_active Expired - Fee Related
- 1997-09-15 WO PCT/EP1997/005040 patent/WO1998013034A1/en not_active Application Discontinuation
- 1997-09-15 AT AT97910289T patent/ATE239459T1/de not_active IP Right Cessation
- 1997-09-15 EP EP97910289A patent/EP0973511B1/en not_active Expired - Lifetime
- 1997-09-15 PL PL97332367A patent/PL190017B1/pl not_active IP Right Cessation
- 1997-09-15 CZ CZ1999932A patent/CZ291879B6/cs not_active IP Right Cessation
- 1997-09-15 NZ NZ334550A patent/NZ334550A/xx not_active IP Right Cessation
- 1997-09-15 PT PT97910289T patent/PT973511E/pt unknown
- 1997-09-15 SK SK320-99A patent/SK284282B6/sk unknown
- 1997-09-15 IL IL12882097A patent/IL128820A/en not_active IP Right Cessation
- 1997-09-15 BR BR9711411A patent/BR9711411A/pt not_active IP Right Cessation
- 1997-09-15 KR KR1019997002490A patent/KR100573333B1/ko not_active IP Right Cessation
- 1997-09-15 DK DK97910289T patent/DK0973511T3/da active
- 1997-09-15 RU RU99108731/14A patent/RU2197959C2/ru active
- 1997-09-15 UA UA99042290A patent/UA63916C2/uk unknown
- 1997-09-15 HU HU9903823A patent/HU224711B1/hu active IP Right Grant
-
1999
- 1999-03-15 BG BG103249A patent/BG64472B1/bg unknown
- 1999-03-24 NO NO991424A patent/NO991424L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4143126B2 (ja) | 低脂質値のためのシブトラミン類似物の使用 | |
KR100432825B1 (ko) | 식이 장애 치료용 약제학적 조성물 | |
JP2001503737A (ja) | 糖尿病の発生を防止するためのシブトラミン類似体の利用 | |
JP2001501608A (ja) | 医学的処理 | |
US6376552B1 (en) | Treatment of gallstones | |
WO2000056318A1 (en) | Treatment of neuropathic pain or fibromyalgia | |
US6232347B1 (en) | Treatment of osteoarthritis | |
AU773490B2 (en) | Treatment of osteoarthritis | |
JP2002539254A (ja) | 血小板粘着性を低下させるための治療 | |
US20040198837A1 (en) | Treatment of neuropathic pain or fibromyalgia | |
JP2002539250A (ja) | 肺高血圧症の治療 | |
US6433020B1 (en) | Treatment of cardiovascular disease | |
WO2000056319A1 (en) | Treatment of orthostatic hypotension | |
KR20030006909A (ko) | 열공 탈장의 치료 | |
MXPA99002633A (en) | Use of sibutramine analogues to lower lipid levels | |
JP2002539255A (ja) | 体重増加に関係する癌の治療 | |
JP2002539252A (ja) | 胆石の治療 | |
JP2002539253A (ja) | 妊娠後の減量 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040818 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040818 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080527 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080616 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110620 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120620 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130620 Year of fee payment: 5 |
|
LAPS | Cancellation because of no payment of annual fees |